Information on EC 1.3.1.21 - 7-dehydrocholesterol reductase

for references in articles please use BRENDA:EC1.3.1.21
Word Map on EC 1.3.1.21
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY hide
1.3.1.21
-
RECOMMENDED NAME
GeneOntology No.
7-dehydrocholesterol reductase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
cholesterol + NADP+ = cholesta-5,7-dien-3beta-ol + NADPH + H+
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
oxidation
-
-
-
-
redox reaction
-
-
-
-
reduction
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
cholesterol biosynthesis I
-
-
cholesterol biosynthesis II (via 24,25-dihydrolanosterol)
-
-
cholesterol biosynthesis III (via desmosterol)
-
-
plant sterol biosynthesis
-
-
cholesterol biosynthesis
-
-
Steroid biosynthesis
-
-
Metabolic pathways
-
-
Biosynthesis of secondary metabolites
-
-
SYSTEMATIC NAME
IUBMB Comments
cholesterol:NADP+ DELTA7-oxidoreductase
The enzyme is part of the cholesterol biosynthesis pathway.
CAS REGISTRY NUMBER
COMMENTARY hide
9080-21-1
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
UniProt
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
maize
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
metabolism
physiological function
additional information
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
7-dehydrodesmosterol + NADPH
desmosterol + NADP+
show the reaction diagram
7-dehydrositosterol + NADPH
sitosterol + NADP+
show the reaction diagram
-
25% of that with 7-dehydrocholesterol
-
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
show the reaction diagram
cholesta-5,7-dien-3alpha-ol + NADPH
epicholesterol + NADP+
show the reaction diagram
-
i.e. 7-dehydroepicholesterol, 25% activity of that with 7-dehydrocholesterol
-
-
-
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
show the reaction diagram
cholesta-5,7-dien-3beta-ol + NADPH + H+
cholesterol + NADP+
show the reaction diagram
-
-
-
-
?
cholesta-7-en-3beta-ol + NADPH
?
show the reaction diagram
cholesterol + NADP+
cholesta-5,7-dien-3-beta-ol + NADPH + H+
show the reaction diagram
-
-
-
?
cholesterol + NADP+
cholesta-5,7-dien-3beta-ol + NADPH + H+
show the reaction diagram
cholesterol + O2 + NAD(P)H + H+
cholesta-5,7-dien-3beta-ol + NAD(P)+ + 2 H2O
show the reaction diagram
desmosterol + NADP+
7-dehydrodesmosterol + NADPH + H+
show the reaction diagram
ergosta-5,7,22-trien-3beta-ol + NADPH
ergosta-5,22-diene-3beta-ol + NADP+
show the reaction diagram
ergosta-5,7-diene-3beta-ol + NADPH
ergosta-5-ene-3beta-ol + NADP+
show the reaction diagram
ergosta-5,7-diene-3beta-ol + NADPH
ergosta-5-eneol + NADP+
show the reaction diagram
-
-
?
ergosta-5,7-dienol + NADPH
ergosta-5-enol + NADP+
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
7-dehydrodesmosterol + NADPH
desmosterol + NADP+
show the reaction diagram
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
show the reaction diagram
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
show the reaction diagram
cholesta-5,7-dien-3beta-ol + NADPH + H+
cholesterol + NADP+
show the reaction diagram
-
-
-
-
?
cholesterol + NADP+
cholesta-5,7-dien-3beta-ol + NADPH + H+
show the reaction diagram
cholesterol + O2 + NAD(P)H + H+
cholesta-5,7-dien-3beta-ol + NAD(P)+ + 2 H2O
show the reaction diagram
Q17938
first committed step in biosynthesis of Caenorhabditis elegans bile acid-like steroids called dafachronic acids
-
-
?
desmosterol + NADP+
7-dehydrodesmosterol + NADPH + H+
show the reaction diagram
ergosta-5,7-diene-3beta-ol + NADPH
ergosta-5-ene-3beta-ol + NADP+
show the reaction diagram
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Iron
-
iron-dependent
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(+)-pachysamine B
-
-
-
1,4-bis-[2-chlorobenzylaminomethyl]-cyclohexane
-
AY-9944
1-[3-(2,4,6-trimethoxybenzoyl)propyl]-pyrrolidinium chloride
-
-
-
1-[p-(beta-Diethylaminoethoxy) phenyl]1-(p-tolyl)-2-(p-chlorophenyl)ethanol
-
i.e. MER-29 or triparanol
2-[2-(4-chlorophenyl)ethyl]-6-hydroxy-7-methoxy-1,2,3,4-tetrahydroisoquinoline
-
strong and selective inhibition of 7-dehydrocholesterol reductase, stronger inhibition of overall cholesterol biosynthesis than BM 15.766, presently the most selective known inhibitor of 7-DHCR
20,25-Diazacholesterol
-
-
25-hydroxyvitamin D3
-
-
3'-methoxy-4'-hydroxyclomiphene
-
-
-
3beta-[2-(diethylamino)ethoxy]androst-5-en-17-one
-
i.e. U18666A
4-(2-[1-(n-chlorocinnamyl) piperazin-4-yl] ethyl) benzoic acid
6,7-diaza-5alpha-cholest-8(14)-en-3beta-ol
-
-
6,7-diaza-5beta-cholest-8(14)-en-3beta-ol
-
-
6-aza-B-homo-5alpha-cholest-7-en-3beta-ol
-
-
6-aza-B-homo-5alpha-cholest-8-en-3beta-ol
-
-
7-dehydrocholesterol
8beta-cyano-6,7-diaza-5alpha-cholest-5,8(14)-dien-3beta-ol
-
-
-
acebutolol
-
-
afimoxifene
-
-
-
altanserin
-
-
-
aripiprazole
-
-
AY9944
BM 15.766
-
-
BM15.766
brassicasterol
-
higher concentration, competitive
buspirone
-
-
captopril
-
-
CGS 12066B
-
-
-
Chloropromazine
-
-
cholest-5,7-dien-3beta-ol
-
-
cisapride
-
-
clobenpropit
-
-
clozapine
-
-
cyclopamine
-
dofetilide
-
-
donepezil
-
-
doxorubicin
-
-
droperidol
-
-
-
E-4031
-
-
-
EDTA
-
-
epicholesterol
-
higher concentration, competitive
epipachysamine D
-
-
-
ergosterol
-
non-competetively, concentration 0.025 mM
esmolol
-
-
-
fluoxetine
-
-
formoterol
-
-
-
haloperidol
ifenprodil
-
-
isoxsuprine
-
-
-
lobeline
-
-
-
lofexidine
-
-
-
loxoprofen
-
-
LY-117018
-
-
-
monomethylarsonous acid
-
-
N-(1,5,9-trimethyldecyl-)-4alpha,10-dimethyl-8-aza-trans-decalin-3beta-ol
-
-
-
N-(3-trifluoromethylphenyl)piperazine
-
-
-
N-nitrosodimethylamine
-
-
-
nafadotride
-
-
-
nafoxidine
-
-
naftopidil
-
-
-
nefazodone
-
-
ochratoxin A
-
-
oxybutynin
-
-
pergolide
-
-
-
perospirone
-
-
-
pirenperone
-
-
-
potassium dichromate
-
-
-
proadifen
-
-
-
procaine
-
-
progesterone
-
-
rel-ormeloxifene
-
-
-
risperidone
-
-
salmeterol
-
-
simvastatin
-
-
sitosterol
-
higher concentration, competitive
tamoxifen
-
-
tesmilifene
-
-
trans-1,4-Bis-(2-chlorobenzylaminomethyl)cyclohexane dihydrochloride
trazodone
-
-
-
trioxifene
-
-
-
Triparanol
-
-
vesamicol
-
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
Lipid transfer protein
-
cytosolic, activity enhancement which is inhibited by addition of Tween 80, probably identical with sterol carrier protein
-
Sterol carrier protein
-
from cytosol, required for activity, probably identical with lipid transfer protein
sterol regulatory element
-
two sterol regulatory elements that bind sterol regulatory element-binding protein-2 work in cooperation to synergistically activate the enzyme
-
sterol regulatory element-binding protein cleavage-activating protein
-
-
-
Tween 80
-
can substitute carrier protein
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1.14
7-dehydrocholesterol
0.21
ergosterol
-
-
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0014
20,25-Diazacholesterol
-
-
0.00005
6,7-diaza-5alpha-cholest-8(14)-en-3beta-ol
-
-
0.00007
6-aza-B-homo-5alpha-cholest-7-en-3beta-ol
-
-
0.5
cholest-5,7-dien-3beta-ol
-
-
0.000109 - 0.00024
trans-1,4-Bis-(2-chlorobenzylaminomethyl)cyclohexane dihydrochloride
0.047 - 0.083
Triparanol
-
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0006
(+)-pachysamine B
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0005
2-[2-(4-chlorophenyl)ethyl]-6-hydroxy-7-methoxy-1,2,3,4-tetrahydroisoquinoline
Homo sapiens
-
whole-cell assay, pH not specified in the publication, temperature not specified in the publication
0.000022
3'-methoxy-4'-hydroxyclomiphene
Homo sapiens
-
pH and temperature not specified in the publication
-
0.0000023
BM 15.766
Homo sapiens
-
whole-cell assay, pH not specified in the publication, temperature not specified in the publication
0.00015
doxorubicin
Homo sapiens
-
pH and temperature not specified in the publication
0.02
epipachysamine D
Homo sapiens
-
pH and temperature not specified in the publication
-
0.000012
tamoxifen
Homo sapiens
-
pH and temperature not specified in the publication
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.00011
-
testis enzyme, extract
0.000605
-
-
0.000756
-
-
0.00108
-
solubilized by 1.5% 3-[3-(cholamidopropyl)-dimethylammonio]-1-propanesulfonate, i.e. CHAPS, from microsomes
0.0023
-
liver enzyme, extract
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5.6
-
acetate buffer
6.2
-
citrate buffer
6.8
-
assay at
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
30
-
assay at
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
of healthy persons, heterozygous persons, and Smith-Lemli-Opitz syndrome patients
Manually annotated by BRENDA team
-
exocrine, high desmosterol synthesis
Manually annotated by BRENDA team
-
of healthy persons, heterozygous persons, and Smith-Lemli-Opitz syndrome patients
Manually annotated by BRENDA team
-
coexpression of enzyme and Sonic Hedgehog, Shh, during midline development in embryo. Enzyme functions as an negative regulator in Hedghog signaling at the level or downstream of Smoothend and affects intracellular Hedgehog signaling
Manually annotated by BRENDA team
with holoprosencephaly at gestation age of 21 to 33 weeks
Manually annotated by BRENDA team
-
human epidermal keratinocyte
Manually annotated by BRENDA team
-
progenitor cells, immature cells, and adult cells, differentially expressed transcripts and enzyme expression levels during development and differentiation, overview
Manually annotated by BRENDA team
-
15-20% of total activiy in brain, lipid exchange between microsomes and myelin
Manually annotated by BRENDA team
-
during early embryonic development, the expression of Xdhcr7 is first of all spatially restricted to the Spemann’s organizer and later to the notochord. In both tissues, Xdhcr7 is coexpressed with Sonic hedgehog, Shh
Manually annotated by BRENDA team
-
-
Manually annotated by BRENDA team
-
during early embryonic development, the expression of Xdhcr7 is first of all spatially restricted to the Spemann’s organizer and later to the notochord. In both tissues, Xdhcr7 is coexpressed with Sonic hedgehog, Shh
Manually annotated by BRENDA team
-
low activity
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
Dhcr7 is a nine-pass transmembrane protein in the endoplasmic reticulum
Manually annotated by BRENDA team
additional information
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
53970
calculated from amino acid sequence
54200
-
? * 54200, SDS-PAGE
55000
-
x * 55000, SDS-PAGE
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
phosphoprotein
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
inhibition of AMP-activated protein kinase or protein kinase A abolishes enzyme activity
-
Tween 80 stabilizes during enzyme assay
UVB irradiation does not affect enzyme activity
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
analysis of differentially expressed transcripts of gene dhcr7 in progenitor Leydig cells and in immature Leydig cells, increased expression of the enzyme during differentiation process
-
DNA and amino acid sequence determination and polymorphism analysis of DNA from fetae with holoprosencephaly, naturally occurring mutations involved in pathogenesis are G344D, R404C, and G410S, overexpression of wild-type and mutant enzymes in Saccharomyces cerevisiae as myc-tagged proteins
DNA and amino acid sequence determination, gene structure and organization, gene dhcr7 maps to chromosome 11q12-13
-
DNA and amino acid sequence determination, gene structure and organization, gene dhcr7 maps to chromosome 7F5
-
DNA and amino acid sequence determination, gene structure and organization, gene dhcr7 maps to chromosome 8q2.1
-
expressed in CHO-EV and CHO-DHCR24-V5 cells
-
expressed in Saccharomyces cerevisiae
expression in S2 cell
expression in Saccharomyces cerevisiae cells; full length cDNA and 5'-terminal truncated cDNA, for the latter M59 is the first encountered, gene characterization
-
expression in Saccharomyces cerevisiae with c-myc epitope
-
expression in Sf9 cell
-
expression of cDNA in Saccharomyces cerevisiae and overexpression of recombinant protein Escherichia coli, sequence analysis
expression of mouse embryonic fibroblasts, and in GLI1-positive AsPC1 cells
-
gene characterization
-
gene Dhcr7, chromosome mapping to 8q2.1, DNA and amino acid sequence determination and analysis of the full-length gene and the splicing variants Dhcr7-AS-1-5, gene structure, physical map, 5 alternative splicing variants; gene Dhcr7, DNA and amino acid sequence determination and analysis, 1723 nucleotides, about 636 base pairs, gene structure, physical map, transcript half-life, alternative splicing variant 4; gene Dhcr7, DNA and amino acid sequence determination and analysis, gene structure, 1474 nucleotides, about 387 base pairs, physical map, transcript half-life, alternative splicing variant 1; gene Dhcr7, DNA and amino acid sequence determination and analysis, gene structure, 1595 nucleotides, about 508 base pairs, physical map, transcript half-life, alternative splicing variant 2
gene Dhcr7, DNA and amino acid sequence determination and analysis, no alternative splicing
gene dhcr7, maps to chromosome 11q13, determination of gene structure and organisation, DNA sequence determination and analysis of wild-type and natural mutant genes
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
trans-1,4-bis(2-chlorobenzaminomethyl)cyclohexane dihydrochloride, i.e. AY9944, is a competitive inhibitor of DHCR7 enzyme activity and inductor of DHCR7 expression. The DHCR7 expression is also activated by antipsychotic drugs, e.g. clozapine, chlorpromazine, haloperidol, and antidepressants such as imipramine, overview
-
ENGINEERING
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
H190A
mutation within Rieske [2Fe-2S]-motif, complete loss of activity
H282A
mutation within non-heme Fe(II) binding motif, complete loss of activity
C122A
-
mutation within Rieske [2Fe-2S]-motif, complete loss of activity
D234A
-
mutation within non-heme Fe(II) binding motif, complete loss of activity
A247V
-
natural mutant, Smith-Lemli-Opitz syndrome patient, 3.1% of wild-type enzyme activity, disease severity score is not directly correlated
C380Y
-
natural mutant, Smith-Lemli-Opitz syndrome patient, 1.7% of wild-type enzyme activity, disease severity score is not directly correlated
F174S
-
enzyme mutation in patients with Smith-Lemli-Opitz syndrome
F302L
-
the mutation is associated with Lemli-Opitz syndrome
G147D
-
the mutation is associated with Lemli-Opitz syndrome
G303R
-
the mutation is associated with Lemli-Opitz syndrome
G344D
site-directed mutagenesis, analogously to the naturally occurring mutation in holoprosencephaly, 50% reduced enzyme activity compared to the wild-type enzyme
H119L
-
the mutation is associated with Lemli-Opitz syndrome
H301Q
-
the mutation is associated with Lemli-Opitz syndrome
H301R
-
enzyme mutation in patients with Smith-Lemli-Opitz syndrome
H405Y
-
the mutation is associated with Lemli-Opitz syndrome
I251N
mutation isolated in patient with severe form of Smith-Lemli-Opitz syndrome, carrying additional heterozygous mutation E288K
L157P
-
the mutation is associated with Lemli-Opitz syndrome
N274K
-
enzyme mutation in patients with Smith-Lemli-Opitz syndrome
P51H
-
natural mutation present in patient with Smith-Lemli-Opitz syndrome
P51S
-
the mutation is associated with Lemli-Opitz syndrome
R242C
-
the mutation is associated with Lemli-Opitz syndrome
R352Q
-
the mutation is associated with Lemli-Opitz syndrome
R352W
-
the mutation is associated with Lemli-Opitz syndrome
R363C
-
the mutation is associated with Lemli-Opitz syndrome
R466Q
-
natural mutant, Smith-Lemli-Opitz syndrome patient, 1.0% of wild-type enzyme activity, disease severity score is not directly correlated
R540L
-
natural mutation present in patient with Smith-Lemli-Opitz syndrome
S113C
-
the mutation is associated with Lemli-Opitz syndrome
T154M
-
natural mutant, Smith-Lemli-Opitz syndrome patient, 8.2% of wild-type enzyme activity, disease severity score is not directly correlated
T154R
-
the mutation is associated with Lemli-Opitz syndrome
V326L
-
the mutation is associated with Lemli-Opitz syndrome
V326R
-
the mutation is associated with Lemli-Opitz syndrome
V330M
-
the mutation is associated with Lemli-Opitz syndrome
W151X
-
the mutation is associated with Lemli-Opitz syndrome
W182L
-
enzyme mutation in patients with Smith-Lemli-Opitz syndrome
additional information
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
diagnostics
medicine